PERTH, Australia – With another FDA approval in hand for its regenerative tissue portfolio, Brisbane, Australia-based Admedus Ltd. said it expects to become profitable in the next 12 to 18 months. The FDA cleared Vascucel for marketing on Oct. 17, and the company expects to launch the collagen scaffold for repairing vascular tissue in November.